Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biosyent Inc V.RX

Alternate Symbol(s):  BIOYF

Healthcare
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing... see more

Recent & Breaking News (TSXV:RX)

BioSyent Releases Financial Results for Fourth Quarter and Full Year 2021

GlobeNewswire March 9, 2022

BioSyent Schedules Q4 and Full Year 2021 Earnings Release for March 9, 2022

GlobeNewswire March 3, 2022

BioSyent's (TSXV:RX) Board of Directors adopts advance notice by-law

Brieanna McCutcheon  February 11, 2022

BioSyent Adopts Advance Notice By-law

GlobeNewswire February 11, 2022

BioSyent (TSXV:RX) renews NCIB

John Ballem  December 13, 2021

BioSyent Announces Renewal of Normal Course Issuer Bid

GlobeNewswire December 13, 2021

BioSyent Releases Q3 and YTD 2021 Financial Results

GlobeNewswire November 18, 2021

BioSyent (TSXV:RX) subsidiary launches new FeraMAX® Powder 15

Brieanna McCutcheon  October 19, 2021

BioSyent Announces Launch of New FeraMAX® Pd Powder 15

GlobeNewswire October 19, 2021

BioSyent Releases Q2 and H1 2021 Financial Results

GlobeNewswire August 25, 2021

BioSyent Schedules Q2 and H1 2021 Earnings Release for August 25, 2021

GlobeNewswire August 17, 2021

FAX Capital Corp. Reports Second Quarter 2021 Results

GlobeNewswire August 4, 2021

BioSyent Signs Exclusive Technology Agreement

GlobeNewswire July 13, 2021

FAX Capital Announces Investment in BioSyent Inc., Files Early Warning Report

GlobeNewswire June 11, 2021

BioSyent Releases Financial Results for Q1 2021

GlobeNewswire May 27, 2021

BioSyent Schedules Q1 2021 Earnings Release for May 27, 2021

GlobeNewswire May 20, 2021

FeraMAX® Named #1 Recommended Iron Supplement by National Pharmacists and Physicians for Sixth Consecutive Year

GlobeNewswire May 3, 2021

BioSyent to Present at 2021 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 14, 2021

BioSyent Announces Grant of Restricted Share Units

GlobeNewswire March 19, 2021

BioSyent Releases Financial Results for Fourth Quarter and Full Year 2020

GlobeNewswire March 17, 2021